Biotech innovator NeuroScientific Biopharmaceuticals has received the green light from Australia’s drugs regulator to treat ...

Australian TGA approves additional indication for Telix's Illuccix® to include patient selection for PSMA-Targeted ...

A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the ...

An update from Neuroscientific Biopharmaceuticals Ltd. ( ($AU:NSB) ) is now available. NeuroScientific Biopharmaceuticals has received approval ...

Dementia is a condition that results in progressive memory or thinking problems. It's now the most common cause of death in ...

Regulators focused on pragmatic safety messaging this week, with aligned statements that paracetamol remains appropriate in ...

Despite more than 600 reports of "adverse events" for medicinal cannabis in the past three years, the Therapeutic Goods Administration (TGA) is yet to investigate the safety of most medicinal cannabis ...

A new study shows longer-term use of generic ketamine for severe depression is safe and effective, but researchers say access ...

One of the world's first clinical trials into the potential for psychedelic compound psilocybin to prevent disabling cluster ...

A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the ...